Pfizer stock slips into holiday week as CEO filing, vaccine-policy row and biotech IPO news land
Pfizer shares closed down 0.9% at $25.65 Friday after CEO Albert Bourla disclosed a phantom-stock award and expressed frustration over U.S. vaccine policy changes. A European patent ruling kept COVID-era lawsuits in focus. Investors await Tuesday’s open after the holiday and Pfizer’s February 3 results update.
